Dr. Sudha Biddinger receives 2015 Armen H. Tashjian Jr. Award
May 12, 2105: Sudha Biddinger M.D., Ph.D., Assistant Professor of Pediatrics, Boston Children’s Hospital, will receive the 2015 Armen H. Tashjian Jr. Award for Excellence in Endocrine Research at a reception on Tuesday, May 12, where she will deliver the lecture “Flavin containing monooxygenase 3 as a novel mediator of diabetes associated cardiovascular disease.” Dr. Biddinger performed her undergraduate studies at Princeton University and obtained her MD/PhD from the Johns Hopkins School of Medicine. She completed her internship, pediatrics residency, and fellowship in pediatric endocrinology at the Boston Children’s Hospital. During her fellowship, she worked with Dr. C. Ronald Kahn, studying hepatic insulin resistance. In 2009, she joined the faculty of Boston Children’s Hospital. The mission of the Biddinger lab is to dissect the signaling pathways and mechanisms underlying the development of dyslipidemia, atherosclerosis and fatty liver disease in the insulin resistant states of obesity and diabetes. Dr. Biddinger will receive an honorarium of $2,500 and a medallion minted with the likeness of Professor Tashjian.
About Armen H. Tashjian Jr.
Professor of Toxicology, Emeritus, and former chair of the then-named Department of Molecular and Cellular Toxicology at the Harvard T.H. Chan School of Public Health, Tashjian was celebrated for his neuroendocrine research, contributing to a life-saving test for a pre-cancerous condition associated with inherited thyroid cancer and playing a key role in the development of two drugs for the treatment and prevention of osteoporosis. He also was Professor of Biological Chemistry and Molecular Pharmacology, Emeritus at Harvard Medical School. He received the HSPH Faculty Emeritus Award of Merit for his significant contributions to the field of pharmacology.
In 1953, Tashjian was graduated from Yale University and earned his M.D. from HMS in 1957. After working at the NIH, he returned to HMS in 1961 and the Harvard School of Dental Medicine, where he became an expert in parathyroid hormone and calcium metabolism. Tashjian was appointed professor of toxicology at the Harvard Chan School in 1978. Then-Dean Howard Hiatt tapped him to head a new Laboratory of Toxicology, and Tashjian began to enthusiastically build a cadre of molecular and cellular biologists. The lab developed into the Department of Molecular and Cellular Toxicology, which he chaired.
He was a leading figure in guiding the development of two major drugs in the bone field – raloxifene as a bone resorption inhibitor, used to help prevent and treat osteoporosis and in the prevention of breast cancer, and PTH as an anabolic agent.
Tashjian trained more than 100 graduate students and postdoctoral fellows. His leadership contributions extended beyond his own research and students. He was President of the International Bone and Mineral Society from 1989-1992 and Vice-President from 1986-1989, reflecting the great respect for him internationally in the bone field. He was president of the American Society for Bone and Mineral Research from 1989-1990, and was a recipient of the Astwood Award from the Endocrine Society for basic scientific discoveries in skeletal biology and neuroendocrinology, and of the Endocrine Society’s Distinguished Leadership Award. He was a person of great integrity and scholarship, much loved by his many friends and colleagues, a man of great talent and intellect, but reserved and indeed humble, and with an ever-present sense of humor.
He passed away on July 3, 2009.